share_log

4D Pharma (LON:DDDD) Trading Up 5%

4D Pharma (LON:DDDD) Trading Up 5%

4D Pharma(LON:DDDD)股價上漲5%
Financial News Live ·  2022/09/14 00:23

4D pharma plc (LON:DDDD – Get Rating)'s share price was up 5% during trading on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). Approximately 912,370 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).

4D Pharma plc(LON:DDDD-GET Rating)的股價在週二的交易中上漲了5%。該股最高交易價格為16.86英鎊(0.2美元),最新交易價格為16.66英鎊(0.2美元)。午盤成交量約為912,370股,較2,957,490股的日均成交量下降了69%。該股此前的收盤價為15.86英鎊(0.19美元)。

4D pharma Stock Up 5.0 %

4D製藥類股上漲5.0%

The company has a quick ratio of 4.72, a current ratio of 5.21 and a debt-to-equity ratio of 39.50. The company has a fifty day simple moving average of GBX 16.66 and a 200 day simple moving average of GBX 28.63. The firm has a market capitalization of £30.04 million and a P/E ratio of -1.08.

該公司的速動比率為4.72,流動比率為5.21,債務權益比為39.50。該公司的50日簡單移動均線為16.66英鎊,200日簡單移動均線為28.63英鎊。該公司的市值為3004萬GB,市盈率為-1.08。

About 4D pharma

關於4D製藥

(Get Rating)

(獲取評級)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.

4D製藥公司及其子公司在英國開發活的生物治療產品(LBPS)。該公司開發治療候選藥物,包括用於治療癌症和免疫腫瘤學疾病的MRx0518;用於治療哮喘的MRx-4DP0004;用於治療中樞神經系統疾病的MRx0029和MRx0005;用於腸易激綜合徵的Blautix;以及用於兒童克羅恩病的Thetanix。

Further Reading

進一步閲讀

  • This Is What To Expect From The S&P 500 Now
  • The Two Things You Need To Know About Oracle's FQ1 Report
  • Three Value Stocks For A Volatile Market
  • 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
  • Do These Dividend Achievers Deserve A Place In Your Portfolio?
  • 這就是現在對標準普爾500指數的預期
  • 關於甲骨文的FQ1報告,你需要知道的兩件事
  • 波動市場的三隻價值股
  • 3個能源類股接近突破杯形格局
  • 這些股息獲得者值得在你的投資組合中佔有一席之地嗎?

Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.

接受4D藥房日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對4D製藥及相關公司評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論